Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial (2022)
Attributed to:
A Dose Reduction Immunobridging Study of two HPV vaccines in Tanzanian girls
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Journal Article/Review
Volume: 10
Parent Publication: LANCET GLOBAL HEALTH
Issue: 10
ISSN: 2214-109X